ClinicalTrials.gg
CompletedNCT06766825THALASSAUpdated Oct 8, 2026

Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)

A Phase 2 interventional study of Plitidepsin 1.5 mg/day and Placebo in Post COVID-19 Condition, Long COVID Syndrome and Persistent COVID-19, sponsored by Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · Phase 2, Interventional, and Treatment

How we know

Updated Oct 8, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain — 13 open to participants now, 16 under way, 1 of them phase 3. Post-Acute COVID-19 Syndrome · Spain.

Enrollment
11th of 39
90 · median 60
Started
2025
with 6 others
Phase 2
6 of 52
1 open now
Registered
39th of 52
by date
Lead sponsor
4 of 52
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

Among the 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain, this one is the 11th largest by enrollment of the 39 interventional ones that give a count, is one of 7 that started in 2025, is one of 6 in phase 2, and was the 39th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

13 of the 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain, or all of them as a file.
02

Study summary

The study aims to prove that plitidepsin could be an efficacious, safe, and well-tolerated therapy for PCC. To this end, we will perform a randomized, double-blind study comparing the clinical and laboratory benefits of plitidepsin vs. placebo in 90 subjects with moderate to severe functional disability. The study consists of an intervention period and a follow-up period, with a total of 135 +/-3 days approximately between both periods.

During the intervention period, four treatment cycles will be administered, scheduled every 15 days (every 2 weeks), with intravenous (IV) infusion over three consecutive days. After completing the intervention period, a 90-day (+/-5) follow-up period will be conducted.

Subjects in arm A will receive the plitidepsin 1.5 mg/day 1h-IV during the four treatment periods on Days 1 to 3, Days 15 to 17, Days 29 to 31 and Days 43 to 45. Subjects in arm B will receive 1h-IV placebo 1 vial /day during the first two treatment periods and will receive the plitidepsin 1.5 mg/day 1h-IV during the last two treatment periods. Subjects in arm C will receive 1h-IV placebo 1 vial/day during the four treatment periods.

Read the detailed description

Plitidepsin, a marine-derived cyclic depsipeptide that inhibits SARS-CoV-2 replication at nanomolar concentrations by targeting the host protein eukaryotic translation elongation factor 1A, could be a suitable candidate treatment for "Long COVID" because of a triple mechanism of action; a) it has demonstrated potent anti-SARS-CoV-2 in vitro activity, (b) it has a systemic anti-inflammatory effect, detailed in the text below, and (c) has an anti-herpes antiviral effect, which could provide additional therapeutic benefits to prevent herpesvirus reactivation seen in Long-COVID.

An interim analysis will be conducted upon reaching 30% and 50% of recruitment (patients treated with at least one dose and 28 days (+/- 2 days) of FUP)). The first interim analysis will focus exclusively on safety assessment, based on adverse events reported to date. The second interim analysis (50%) will evaluate safety and futility. A blinded safety report will be prepared, summarizing adverse events, and submitted to the Data Safety Monitoring Board (DSMB) for review and to determine whether to continue, modify, or terminate the study

03

Conditions studied

  • Post COVID-19 Condition
  • Long COVID Syndrome
  • Persistent COVID-19
  • Persistent COVID Condition
  • Long COVID

Keywords

  • SARS-CoV-2
  • COVID-19
  • Long COVID19
  • Plitidepsin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  1. Male or female individuals 18 years old or older.
  2. Evidence of SARS-CoV-2 infection at least 90 days prior to study recruitment, defined by either (a) nasopharyngeal SARS-CoV-2 nucleic acid test [polymerase chain reaction (PCR) or transcription mediated amplification (TMA)], (b) validated Nasopharyngeal Lateral Flow Assay rapid antigen test (RAT), or (c) or positive serology against SARS-CoV-2 N protein regardless vaccination status.
  3. 3 or more symptoms of PCC affecting at least two organs, after 90 days from the onset of SARS-CoV2 infection and that last for at least 2 months and cannot be explained by an alternative diagnosis. Symptoms may be new onset following initial recovery from an acute COVID-19 episode or persist from the initial illness. Symptoms may also fluctuate or relapse over time.
  4. Unable to perform all usual duties/activities, defined as grades 3 or 4 in PCFS (Annex 3).
  5. Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study.
  6. Having understood the information provided and capable of providing

EXCLUSION CRITERIA

  1. Last SARS-CoV-2 vaccine dose during the previous 30 days.
  2. Patients with active uncontrolled infections.
  3. Patients infected by SARS-CoV-2 virus in the last 90 days prior to the screening visit.
  4. Patients receiving treatment with strong cytochrome P450 3A4 () inhibitors or inducers (Annex 1) throughout plitidepsin treatment period and until 24-h .
  5. Pacients receiving chronic therapy (high-dose corticosteroids [ie, 20 mg of prednisone daily or equivalent for ≥2 weeks)
  6. Any of the following cardiac conditions or risk factors:

    • Cardiac infarction or cardiac surgery episode within the last six months 14
    • History of known congenital ;
    • Known structural cardiomyopathy with abnormal (LVEF) \<50%;
    • Current clinical evidence of heart failure or acute cardiac ischaemia ( (NYHA) class III-IV).
  7. to the active ingredient or any of the (mannitol, macrogolglycerol hydroxystearate, and ethanol) or to receive systemic glucocorticoids, antihistamine H1/H2 receptor agents, or antiserotonine 5HT3 receptors drugs.
  8. Mast cell activation syndrome.
  9. Females who are pregnant (negative serum or urine pregnancy test required for all females of at screening) or breast-feeding.
  10. Females of childbearing potential (females who are not surgically sterile or defined as amenorrhea for >12 months) who are not using highly effective methods, while on study treatment and for 6 months after last dose of plitidepsin. Fertile males with partners of childbearing potential must use condom during treatment and for 6 months after last dose of plitidepsin. Refer to Annex 2 for contraception requirements.
  11. Unable to consent and/or comply with study requirements, in the opinion of the investigator.
  12. Currently participating or participated in a clinical trial within the prior
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    A. Plitidepsin Arm

    Subjects in arm A will receive the plitidepsin 1.5 mg/day 1h-IV during the four treatment periods on Days 1 to 3, Days 15 to 17, Days 29 to 31 and Days 43 to 45.

    Drug: Plitidepsin 1.5 mg/day

  • Experimental
    B. Placebo/Plitidepsin

    Subjects in arm B will receive 1h-IV placebo 1 vial /day during the first two treatment periods (Days 1 to 3 and Days 15 to 17) and plitidepsin 1.5 mg/day 1h-IV during the last two treatment periods (Days 29 to 31 and Days 43 to 45).

    Drug: Placebo and Plitidepsin 1.5mg/day

  • Placebo comparator
    C. Placebo Arm

    Subjects in arm C will receive 1h-IV placebo 1 vial/day during the four treatment periods on Days 1 to 3, Days 15 to 17, Days 29 to 31, and Days 43 to 45.

    Drug: Placebo

Interventions

  • DrugPlitidepsin 1.5 mg/day

    Drug page: PlitidepsinStudies of PlitidepsinPlitidepsin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Receive 1.5 mg/day of plitidepsin intravenously (IV) over a 1-hour infusion for 3 consecutive days every 15 days during 4 treatment periods. The participant will receive the following pre-medication before receiving the study treatment: * Palonosetron 0.25 mg IV * Dexchlorpheniramine maleate 5 mg IV (or equivalent to H1 receptor antihistamines) * Famotidine 40 mg oral (60 minutes before starting the plitidepsin/placebo infusion) * Dexamethasone phosphate 8 mg IV (equivalent to 6.6 mg of dexamethasone) Premedication should be completed 20-30 minutes before starting the plitidepsin/placebo infusion.

  • DrugPlacebo

    Receive placebo intravenously (IV) over a 1-hour infusion for 3 consecutive days every 15 days during 4 treatment periods. The participant will receive the following pre-medication before receiving the study treatment: * Palonosetron 0.25 mg IV * Dexchlorpheniramine maleate 5 mg IV (or equivalent to H1 receptor antihistamines) * Famotidine 40 mg oral (60 minutes before starting the plitidepsin/placebo infusion) * Dexamethasone phosphate 8 mg IV (equivalent to 6.6 mg of dexamethasone) Premedication should be completed 20-30 minutes before starting the plitidepsin/placebo infusion.

  • DrugPlacebo and Plitidepsin 1.5mg/day

    Receive placebo intravenously (IV) over a 1-hour infusion for 3 consecutive days every 15 days during two treatment periods and receive plitidepsin 1.5mg/day during the last two treatment periods. The participant will receive the following pre-medication before receiving the study treatment: * Palonosetron 0.25 mg IV * Dexchlorpheniramine maleate 5 mg IV (or equivalent to H1 receptor antihistamines) * Famotidine 40 mg oral (60 minutes before starting the plitidepsin/placebo infusion) * Dexamethasone phosphate 8 mg IV (equivalent to 6.6 mg of dexamethasone) Premedication should be completed 20-30 minutes before starting the plitidepsin/placebo infusion.

06

What researchers measure

Primary outcomes

  1. Change in the overall health in patients from each group using patient reported outcomes measurement information system score (PROMIS-29®).

    Difference between groups on the patient-reported outcomes measurement information system (PROMIS-29®) score health scale measured by T-Score; Each domain is scored on a 5-point scale, (without any difficulty, with a little difficulty, with some difficulty, with much difficulty, unable to do), in case of the pain domain is on a 10-point scale; from no pain to the worse pain. on day 90 (±5) of the follow-up period\* (after the intervention).

    Time frame: On day 90 of follow-up period

Secondary outcomes

  1. To compare the safety/tolerability of Plitidepsin Vs placebo in terms of adverse events in patients with PCC.

    The proportion of adverse events (AE, coded by MedDRA) comparing between groups at day 90 (±5) of the follow-up period, considering: 1. All AEs. 2. AEs grade 3 and 4 leading to discontinuation from the study. 3. AEs of special interest (AESI): cardiac, liver, acute-infusional reactions.

    Time frame: On day 90 of follow-up period

  2. To compare the incidence of Treatment-Emergent Adverse Events (TEAEs) between groups.

    Percentage of TEAEs detected on day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period.

    Time frame: On day 10, day 30 and day 90 of follow-up period

  3. To compare changes in the overall health in patients from each group using patient reported outcomes measurement information system score (PROMIS-29®).

    Difference between groups on the PROMIS-29® health scale measured by T-Score on day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period. Each domain is scored on a 5-point scale, (without any difficulty, with a little difficulty, with some difficulty, with much difficulty, unable to do), in case of the pain domain is on a 10-point scale; from no pain to the worse pain. on day 90 (±5) of the follow-up period\* (after the intervention).

    Time frame: On day 10, day 30 and day 90 of follow-up period

  4. To compare functional capacity changes in patients from each group using the post-COVID-19 Functional State (PCFS) scale.

    Difference between groups in functional capacity on the PCFS scale on day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period.

    Time frame: On day 10, day 30 and day 90 of follow-up period

  5. To compare symptomatic changes in patients from each group using the Can Ruti Questionnaire.

    Proportion of subjects with ≥10 points reduction in the Can Ruti Questionnaire scale on day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period.

    Time frame: On day 10, day 30 and day 90 of follow-up period

  6. To compare changes in terms of Quality of Life (QoL) for each group.

    Difference between groups according to the EuroQoL-5D questionnaire on day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period.

    Time frame: On day 10, day 30 and day 90 of follow-up period

  7. To compare neuropsychological symptomatology [psychomotor speed and executive function] in patients with PCC among the three treatment arms.

    Change from baseline\*\* in neuropsychological symptoms to day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period, measured using NeuScreen questionnaire to evaluate the psychomotor speed and executive function measured in seconds.

    Time frame: On day 10, day 30 and day 90 of follow-up period

  8. To compare neuropsychological symptomatology [depressive symptoms] in patients with PCC among the three treatment arms.

    Change from baseline\*\* in neuropsychological symptoms to day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period, using the PHQ-9 score questionnaire to evaluate the depressive symptoms, each question is scored on a 4-point scale, where (0) is the most positive answe and (3) is the worse condition.

    Time frame: On day 10, day 30 and day 90 of follow-up period

  9. To compare neuropsychological symptomatology [ anxiety symptoms] in patients with PCC among the three treatment arms.

    Change from baseline\*\* in neuropsychological symptoms to day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period, using the GAD-7 questionnaire to evaluate anxiety symptoms; Each question is scored as follows: 0 points: "Not at all", 1 point: "Several days", 2 points: "More than half the days", 3 points: "Nearly every day"

    Time frame: On day 10, day 30 and day 90 of follow-up period

  10. To compare neuropsychological symptomatology [sleep quality] in patients with PCC among the three treatment arms.

    Change from baseline\*\* in neuropsychological symptoms to day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period, measured using PSQI to evaluate sleep quality; the scores for the seven components are then summed to yield a global PSQI score, which ranges from 0 to 21. A global score greater than 5 suggests poor sleep quality.

    Time frame: On day 10, day 30 and day 90 of follow-up period

  11. To compare neuropsychological symptomatology [disability] in patients with PCC among the three treatment arms.

    Change from baseline\*\* in neuropsychological symptoms to day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period, using WHODAS 2.0 questionnaire to evaluate disability: Each item is scored on a scale from 1 to 5, with higher scores indicating greater difficulty in functioning. The total score is calculated by summing the scores for all items, and it can be converted into a standardized score ranging from 0 to 100, where higher scores indicate greater disability.

    Time frame: On day 10, day 30 and day 90 of follow-up period

  12. To compare changes in terms of physical activity in patients with PCC among the three arms.

    Change from baseline in physical activity to day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period, assessed using the International Physical Activity Questionnaire (IPAQ).

    Time frame: On day 10, day 30 and day 90 of follow-up period

  13. To compare changes in terms of fatigue (Fatigue scale) in patients with PCC among the three treatment arms.

    Change from baseline in physical activity to day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period, evaluated using the Fatigue Severity Scale (FSS): nine statements, of 7-point Likert scale, where (1- Strongly disagree) and (7-Strongly agree). Higher scores indicate greater fatigue severity.

    Time frame: On day 10, day 30 and day 90 of follow-up period

  14. To compare changes in terms of fatigue (Five times sit to stant test) in patients with PCC among the three treatment arms.

    Change from baseline in physical activity to day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period, evaluated using Five Times Sit-to-Stand Test (5xSTS), The score is the total time in seconds

    Time frame: On day 10, day 30 and day 90 of follow-up period

  15. To compare the evolution of inflammation markers in patients with PCC among the three arms.

    Change from baseline in inflammation markers on day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period.

    Time frame: On day 10, day 30 and day 90 of follow-up period

  16. To compare immune response markers: Antinuclear antibodies (ANAs) in patients with persistent COVID among the three treatment arms.

    Change from baseline in Antinuclear antibodies (ANAs) to day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period. measured in UI/mL.

    Time frame: On day 10, day 30 and day 90 of follow-up period

  17. To compare immune response markers: antiphospholipid antibodies (Abs) in patients with persistent COVID among the three treatment arms.

    Change from baseline in antiphospholipid antibodies (Abs),) to day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period. measured in UI/mL.

    Time frame: On day 10, day 30 and day 90 of follow-up period

  18. To compare immune response markers: antimitochondrial antibodies in patients with persistent COVID among the three treatment arms.

    Change from baseline in antimitochondrial antibodies to day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period. measured in UI/mL.

    Time frame: On day 10, day 30 and day 90 of follow-up period

  19. To compare the SARS-CoV-2 RNA antigenemia (presence of viral components) in plasma with persistent COVID among the three treatment arms.

    Change from baseline in viral components (SARS-CoV-2 RNA antigenemia) in plasma to day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period. The SARS-CoV-2 RNA is quantified in pg/mL.

    Time frame: On day 10, day 30 and day 90 of follow-up period

  20. To compare alterations in Complement Activitation: Hemolytic Complement CH50 in patients with persistent COVID among the three treatment arms.

    Change from baseline in Complement Activity: Hemolytic Complement CH50 to day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period. measured in UI/mL.

    Time frame: On day 10, day 30 and day 90 of follow-up period

  21. To compare alterations in thromboinflammatory components (prothrombin time (PT)), among the three treatment arms.

    Change from baseline in prothrombin time (PT) ratio in plasma to day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period.

    Time frame: On day 10, day 30 and day 90 of follow-up period

  22. To compare alterations in thromboinflammatory components (activated partial thromboplastin time (aPTT)), among the three treatment arms.

    Change from baseline in activated partial thromboplastin time (aPTT) in seconds, in plasma to day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period.

    Time frame: On day 10, day 30 and day 90 of follow-up period

  23. To compare alterations in thromboinflammatory components (D-Dimer), among the three treatment arms.

    Change from baseline in D-Dimer measured in ng/mL, in plasma to day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period.

    Time frame: On day 10, day 30 and day 90 of follow-up period

  24. To compare alterations in thromboinflammatory components (Fibrinogen), among the three treatment arms.

    Change from baseline in Fibrinogen measured in mg/dL, in plasma to day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period.

    Time frame: On day 10, day 30 and day 90 of follow-up period

  25. To compare alterations in thromboinflammatory components (Antithrombin III (ATIII)), among the three treatment arms.

    Change from baseline in Antithrombin III (ATIII) measured in %, in plasma to day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period.

    Time frame: On day 10, day 30 and day 90 of follow-up period

  26. To compare alterations in thromboinflammatory components (Factor de Von willebrand), among the three treatment arms.

    Change from baseline in Factor de Von Willebrand measured in %, in plasma to day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period.

    Time frame: On day 10, day 30 and day 90 of follow-up period

  27. To compare alterations in hormonal components (Serotonin) among the three treatment arms.

    Change from baseline in serotonin (UI) in plasma to day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period.

    Time frame: On day 10, day 30 and day 90 of follow-up period

  28. To compare alterations in hormonal components (Dopamine) among the three treatment arms.

    Change from baseline in dopamine alterations in plasma to day 10 (±2), day 30 (±2), and day 90 (±5) of the follow-up period. measured in ug/24 h

    Time frame: On day 10, day 30 and day 90 of follow-up period

07

Study locations

1 site
  • Hospital Universitari Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Sep 2026, 19 months.

Of 46 non-industry phase 2 interventional studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 24. This study's 19 months is above that.

Counting every sponsor, half of 63 studies reached it within 17 months; a quarter within 12 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 31, 2024
First posted
Jan 9, 2025
StartActual
Feb 7, 2025
Primary completionActual
Sep 29, 2026
CompletionActual
Sep 29, 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 8, 2026
Primary completion
Sep 10, 2026→Sep 29, 2026 (actual)
Oct 8, 2026
Study completion
Sep 10, 2026→Sep 29, 2026 (actual)
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Active, not recruiting→Completed
    Primary completion Sep 10, 2026→Sep 29, 2026 (now actual)
    Study completion Sep 10, 2026→Sep 29, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06766825
Lead sponsor
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Collaborators
PharmaMar, IrsiCaixa
Responsible party
Sponsor
First posted
Jan 9, 2025
Start date
Feb 7, 2025
Primary completion
Sep 29, 2026
Completion
Sep 29, 2026
Last update
Oct 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Plitidepsin

Start the discussion